Treatment of Co-occurring Tic Disorder and OCD

Initial Assessment and Treatment Planning

The British journal of neurosurgery suggests establishing which disorder is primary and most disabling to determine treatment priorities, as this approach helps in focusing on the predominant problem, whether it be tics or OCD symptoms, and adjusting treatment accordingly 3, 4
When tics are the predominant problem, the British journal of neurosurgery recommends focusing on tic management first, and when OCD symptoms cause greater impairment, prioritizing OCD treatment while monitoring for tic exacerbation 4

The American College of Cardiology is not mentioned, however, the Praxis Medical Insights recommends starting with cognitive-behavioral therapy (CBT) with exposure and response prevention (ERP) for OCD symptoms, with patient adherence to between-session homework being the strongest predictor of success, typically requiring 10-20 sessions 1, 2

The Praxis Medical Insights recommends beginning with an SSRI at higher doses than used for depression or anxiety disorders, with fluoxetine specifically started at 20 mg daily and titrated to 40-60 mg daily for OCD, and administering for a minimum of 8-12 weeks at maximum tolerated dose before declaring treatment failure 1, 2
The Nature Reviews Disease Primers suggests that when SSRI response is partial after 8-12 weeks, adding low-dose antipsychotic augmentation, such as risperidone or aripiprazole, can address both residual OCD symptoms and tics simultaneously, with close monitoring of metabolic parameters due to the risk of weight gain and metabolic dysregulation 2, 5
The Praxis Medical Insights recommends considering N-acetylcysteine or memantine augmentation if antipsychotic augmentation fails or is not tolerated, as these agents have shown efficacy in treatment-resistant OCD 2, 5

The British journal of neurosurgery and Nature Reviews Disease Primers suggest considering neuromodulation approaches, such as deep repetitive transcranial magnetic stimulation (rTMS) or deep brain stimulation (DBS), for severe, intractable cases unresponsive to multiple medication trials and intensive behavioral therapy, with DBS reserved for less than 1% of treatment-seeking individuals and requiring specific eligibility criteria, including age, treatment-refractory status, and severe functional impairment 2, 3, 4, 5
The British journal of neurosurgery recommends that DBS eligibility criteria include age >20 years, treatment-refractory after failing behavioral therapy and at least three medications, tics as the primary problem, and severe functional impairment with documented impact on health-related quality of life 3, 4

The Praxis Medical Insights suggests that both conditions typically require chronic treatment, with maintenance therapy often needed for 12-24 months or longer, and periodic reassessment of the treatment regimen to balance symptom control with side effect management, and recommends monthly booster CBT sessions for 3-6 months after initial treatment to help maintain gains 1, 2, 6
The British journal of neurosurgery and Nature Reviews Disease Primers recommend regular quality of life assessment, as both disorders significantly reduce functioning across work, family, and social domains 2, 3, 4, 5